Semler Scientific Hits 52-Week Low at $21.84 Amid Ongoing Struggles

Semler Scientific, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 21.84 on October 22, 2025. This decline marks a significant downturn for the stock, which has experienced a 37.9% decrease over the past year, contrasting sharply with the S&P 500's performance of 15.06% during the same period.
The company's market capitalization stands at USD 425 million, with a price-to-earnings ratio of 24.00. Semler Scientific has not offered any dividends, and its debt-to-equity ratio is reported at -0.04, indicating a unique financial structure. The return on equity is relatively modest at 3.43%, and the price-to-book ratio is 1.11.

Semler has faced challenges in its financial performance, reporting negative results for the last four consecutive quarters. Key metrics such as operating cash flow and net sales have reached their lowest levels, with operating cash flow at USD 12.45 million and net sales at USD 8.22 million. This consistent underperformance against market benchmarks has raised concerns about the company's financial health.